The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Jarnagin W, Chapman WC, Curley S, et al. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB. 2010;12:302–310. doi:10.1111/j.1477-2574.2010.00182.x20590903
   PubMed Web of Science ®Google Scholar
• Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection patterns, treatments, and prognosis. Ann Surg. 2015;261:947–955. doi:10.1097/SLA.000000000000071025010665
   PubMed Web of Science ®Google Scholar
• Shirabe K, Wakiyama S, Gion T, et al. Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma - results of 152 resected cases. Hepato-Gastroenterology. 2007;54:2084–2087.18251164
   PubMedGoogle Scholar
• Wakayama K, Kamiyama T, Yokoo H, et al. Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection. J Surg Oncol. 2017;115:324–329. doi:10.1002/jso.2450128192617
   PubMed Web of Science ®Google Scholar
• Li C, Wen TF, Yan LN, et al. Liver resection versus liver resection plus TACE for patients with hepatocellular carcinoma beyond Milan criteria. J Surg Res. 2017;209:8–16. doi:10.1016/j.jss.2016.09.05428032575
   PubMed Web of Science ®Google Scholar
• Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7. doi:10.1038/s41598-017-12834-1
   Web of Science ®Google Scholar
• Badshah MB, Ghabril M, Fadel W, et al. The role of AFP in screening and diagnosis of viral and non-viral hepatocellular carcinoma (HCC). Hepatology. 2015;62:1136A–1137A.
   Web of Science ®Google Scholar
• Wu W, Yao DF, Qiu LW, Wu XH. Clinical values of combined hepatoma-specific AFP fraction and AFP-mRNA determination in diagnosis and differentiation of hepatocellular carcinoma. Prog Post-Genome Technology; 2006; Hangzhou, China. 443–446.
   Google Scholar
• Kelleher PC, Smith CJP, Ajdukiewicz A. Human alpha-fetoprotein (AFP) - lectin-binding heterogeneity and the early diagnosis of primary hepatocellular-carcinoma (PHC). Proceedings of the American Association for Cancer Research; 1983; Philadelphia, PA. 24:240.
   Google Scholar
• Sang W, Zhang W, Cui WL, Li XX, Abulajiang G, Li QX. Arginase-1 is a more sensitive marker than HepPar-1 and AFP in differential diagnosis of hepatocellular carcinoma from nonhepatocellular carcinoma. Tumor Biol. 2015;36:3881–3886. doi:10.1007/s13277-014-3030-6
   PubMedGoogle Scholar
• Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1. doi:10.4103/jcar.JCar_9_1628694740
   PubMedGoogle Scholar
• Schubert OT, Rost HL, Collins BC, Rosenberger G, Aebersold R. Quantitative proteomics: challenges and opportunities in basic and applied research. Nat Protoc. 2017;12:1289–1294. doi:10.1038/nprot.2017.04028569762
   PubMed Web of Science ®Google Scholar
• Werner T, Becher I, Sweetman G, Doce C, Savitski MM, Bantscheff M. High-resolution enabled TMT 8-plexing. Anal Chem. 2012;84:7188–7194. doi:10.1021/ac301553x22881393
   PubMed Web of Science ®Google Scholar
• Wang YC, Liu HZ, Liang D, et al. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics. J Proteomics. 2017;150:230–241. doi:10.1016/j.jprot.2016.09.00827693406
   PubMed Web of Science ®Google Scholar
• Bhosale SD, Moulder R, Kouvonen P, Lahesmaa R, Goodlett DR. Mass spectrometry-based serum proteomics for biomarker discovery and validation. Methods Mol Biol. 2017;1619:451–466. doi:10.1007/978-1-4939-7057-5_3128674903
   PubMedGoogle Scholar
• Tsai TH, Song EW, Zhu R, et al. LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma. Proteomics. 2015;15:2369–2381. doi:10.1002/pmic.20140036425778709
   PubMed Web of Science ®Google Scholar
• Qin X, Chen QP, Sun C, et al. High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques. Med Oncol. 2013;30. doi:10.1007/s12032-012-0420-8
   Web of Science ®Google Scholar
• Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003;361:923–929. doi:10.1016/S0140-6736(03)12775-412648972
   PubMed Web of Science ®Google Scholar
• Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20:1126–1167. doi:10.1089/ars.2012.514923991888
   PubMed Web of Science ®Google Scholar
• Fidge NH. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res. 1999;40:187–201.9925647
   PubMed Web of Science ®Google Scholar
• Silver DL, Wang N, Xiao X, Tall AR. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J Biol Chem. 2001;276:25287–25293. doi:10.1074/jbc.M10172620011301333
   PubMed Web of Science ®Google Scholar
• Li XJ, Jiang YH, Meisenhelder J, et al. Mitochondria-translocated PGK1 functions as a protein kinase to coordinate glycolysis and the TCA cycle in tumorigenesis. Mol Cell. 2016;61:705–719. doi:10.1016/j.molcel.2016.02.00926942675
   PubMed Web of Science ®Google Scholar
• Xie HJ, Tong GH, Zhang YP, Liang S, Tang KR, Yang QH. PGK1 drives hepatocellular carcinoma metastasis by enhancing metabolic process. Int J Mol Sci. 2017;18. doi:10.3390/ijms18081630
   Web of Science ®Google Scholar
• Ai JZ, Huang HZ, Lv XY, et al. FLNA and PGK1 are two potential markers for progression in hepatocellular carcinoma. Cell Physiol Biochem. 2011;27:207–216. doi:10.1159/00032794621471709
   PubMed Web of Science ®Google Scholar
• Zheng J, Chou JF, Gonen M, et al. Prediction of hepatocellular carcinoma recurrence beyond milan criteria after resection. Ann Surg. 2017;266:693–701.28650354
   PubMed Web of Science ®Google Scholar
• Braillon A. Recurrence in early-stage hepatocellular carcinoma: CpG methylation and smoking. J Clin Oncol. 2017;35:2097-+. doi:10.1200/JCO.2017.72.3932
   Web of Science ®Google Scholar
• Barrett M, Nathan H, Vankayala H, Bieliauskas SL, Viglianti BL, Frankel TL. Recurrence of hepatocellular carcinoma at surgical incision site: case series and review of literature. Ann R Coll Surg Engl. 2017;99:E177–E179. doi:10.1308/rcsann.2017.009728660820
   PubMed Web of Science ®Google Scholar
• Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol. 2015;13:2140–2151. doi:10.1016/j.cgh.2015.08.01426284591
   PubMed Web of Science ®Google Scholar
• Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29:919–928. doi:10.1016/j.bpg.2015.09.00726651253
   PubMed Web of Science ®Google Scholar
• Lazzara C, Navarra G, Lazzara S, et al. Does the margin width influence recurrence rate in liver surgery for hepatocellular carcinoma smaller than 5 cm? Eur Rev Med Pharmacol Sci. 2017;21:523–529.28239817
   PubMed Web of Science ®Google Scholar
• Hwang TL, Liang Y, Chien KY, Yu JS. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics. 2006;6:2259–2272. doi:10.1002/pmic.20050034516493704
   PubMed Web of Science ®Google Scholar
• Sun S, Liang X, Zhang X, et al. Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer. Br J Cancer. 2015;112:1332–1339. doi:10.1038/bjc.2015.11425867275
   PubMed Web of Science ®Google Scholar
• Zieker D, Konigsrainer I, Traub F, et al. PGK1 a potential marker for peritoneal dissemination in gastric cancer. Cell Physiol Biochem. 2008;21:429–436. doi:10.1159/00012963518453750
   PubMed Web of Science ®Google Scholar